CLS Therapeutics

Executive Summary

CLS Therapeutics is a clinical-stage biopharmaceutical company pioneering the use of recombinant human DNase I (rhDNase) to degrade neutrophil extracellular traps (NETs), which are implicated in severe inflammatory and thrombotic conditions. The lead program targets COVID-19-associated acute respiratory distress syndrome (ARDS), with Phase 2 data demonstrating reduced mortality and improved oxygenation. The company is preparing for a pivotal Phase 3 trial, aiming to confirm efficacy in this high-need population. Additionally, CLS is exploring rhDNase in acute myocardial infarction and pancreatitis, where NET-mediated pathology plays a key role. With a robust scientific foundation and a focus on high-impact indications, CLS Therapeutics is positioned to address significant unmet medical needs in critical care and cardiovascular medicine. The company maintains a lean operational model and seeks strategic partnerships to accelerate development and commercialization.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 trial initiation in COVID-19 ARDS40% success
• Q4 2026Phase 2 data readout in acute myocardial infarction30% success
• H2 2026Strategic partnership or licensing deal for non-COVID indications50% success